Key facts
- It has raised $180K; the latest was Accelerator/Incubator in Jan 2026.
- Notable investors include Creative Destruction Lab, US National Science Foundation, Rice University, Community Development Venture Capital Alliance, New Orleans BioInnovation Center — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Informuta
- ·The full record, as it builds
Funding rounds
No funding rounds for Informuta are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Informuta
Developer of precision diagnostic tools designed to analyze whole genome sequencing data to inform clinical treatment decisions. The company diagnoses resistance-prone infections and simultaneously tracks infection spread to improve treatment, decrease incidence, and decrease the cost of resistant infections, enabling hospitals and clinicians to aid in clinical decision-making, treatment, and precision-based care.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2023
- Employees
- 6
- Website
- informuta.com/
- Ownership
- Privately Held (backing)
Informuta doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Informuta shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Informuta in its N-PORT filings yet. We sweep new filings monthly.